Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 1
1988 2
1991 2
1992 2
1999 1
2002 1
2003 1
2004 2
2005 4
2006 6
2007 5
2008 4
2009 4
2010 1
2011 2
2013 5
2014 8
2015 4
2016 2
2017 3
2018 4
2019 1
2020 6
2021 7
2022 12
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Results by year

Filters applied: . Clear all
Page 1
Characterization of cytoskeletal and structural effects of INF2 variants causing glomerulopathy and neuropathy.
Ueda H, Tran QTH, Tran LNT, Higasa K, Ikeda Y, Kondo N, Hashiyada M, Sato C, Sato Y, Ashida A, Nishio S, Iwata Y, Iida H, Matsuoka D, Hidaka Y, Fukui K, Itami S, Kawashita N, Sugimoto K, Nozu K, Hattori M, Tsukaguchi H. Ueda H, et al. Among authors: matsuoka d. Sci Rep. 2023 Jul 25;13(1):12003. doi: 10.1038/s41598-023-38588-7. Sci Rep. 2023. PMID: 37491439 Free PMC article.
Experimental and theoretical investigations into the mechanism of interactions between membrane-bound fatty acids and their binding protein: A model system to investigate the behavior of lipid acyl chains in contact with proteins.
Sugiyama S, Matsuoka D, Hara T, Sonoyama M, Matsuoka S, Murata M. Sugiyama S, et al. Among authors: matsuoka d. Chem Phys Lipids. 2022 Sep;247:105227. doi: 10.1016/j.chemphyslip.2022.105227. Epub 2022 Aug 3. Chem Phys Lipids. 2022. PMID: 35932927 Review.
Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib.
Ida H, Shimizu T, Nishino M, Nakamura Y, Yazaki S, Katsuya Y, Sato J, Koyama T, Iwasa S, Sudo K, Kondo S, Yonemori K, Shitara K, Shiono S, Matsuoka D, Yasuda K, Otake Y, Suzuki T, Takase T, Takashima S, Yamaguchi K, Semba T, Yamamoto N. Ida H, et al. Among authors: matsuoka d. Cancer Res Commun. 2023 Jul 10;3(7):1189-1199. doi: 10.1158/2767-9764.CRC-22-0401. eCollection 2023 Jul. Cancer Res Commun. 2023. PMID: 37435605 Free PMC article. Clinical Trial.
The BeachLitter dataset for image segmentation of beach litter.
Sugiyama D, Hidaka M, Matsuoka D, Murakami K, Kako S. Sugiyama D, et al. Among authors: matsuoka d. Data Brief. 2022 Mar 22;42:108072. doi: 10.1016/j.dib.2022.108072. eCollection 2022 Jun. Data Brief. 2022. PMID: 35392618 Free PMC article.
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort.
Nishio M, Murakami S, Kawakami H, Okishio K, Tamiya M, Kobayashi H, Fujimoto D, Sugawara S, Kozuki T, Oya Y, Izumi H, Shiroyama T, Satouchi M, Yamamoto N, Kaname S, Matsuoka D, Otake Y, Takase T, Semba T, Azuma K. Nishio M, et al. Among authors: matsuoka d. Cancer Res Commun. 2024 Jan 29;4(1):226-235. doi: 10.1158/2767-9764.CRC-23-0313. Cancer Res Commun. 2024. PMID: 38181055 Free PMC article. Clinical Trial.
93 results